Heat shock protein 90 controls HIV-1 reactivation from latency

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 15, 2014, Pages

  Anderson, Ian ^a   Low, Jun Siong ^a   Weston, Stuart ^a   Weinberger, Michael ^a   Zhyvoloup, Alexander ^a   Labokha, Aksana A ^a   Corazza, Gianmarco ^b   Kitson, Russell A ^c   Moody, Christopher J ^c   Marcello, Alessandro ^b   Fassati, Ariberto ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANSAMYCIN DERIVATIVE; CELL CYCLE PROTEIN 37; HEAT SHOCK PROTEIN 90; I KAPPA B; LUMINESPIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE; PROTEIN KINASE C INHIBITOR; PROTEIN P50; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SOTRASTAURIN; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR; ALVESPIMYCIN; GELDANAMYCIN; HISTONE DEACETYLASE INHIBITOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACBECIN I; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN KINASE C; TANESPIMYCIN;

ANIMAL CELL; ARTICLE; CLINICAL TRIAL (TOPIC); COMPLEX FORMATION; DISSOCIATION; DRUG CYTOTOXICITY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; VIRUS LATENCY; VIRUS REACTIVATION; CD4+ T LYMPHOCYTE; DRUG PROTEIN BINDING; ENZYME ACTIVATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LATENT PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; VIRAL CLEARANCE; VIRUS REPLICATION;

BLOTTING, WESTERN; CELL LINE; HIV-1; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPRECIPITATION; MICROSCOPY, FLUORESCENCE; NF-KAPPA B; SIGNAL TRANSDUCTION; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84898772703     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1320178111     Document Type: Article

References (52)

1. Palella FJ, Jr., et al.; HIV Outpatient Study Investigators (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338(13):853-860
2. Finzi D, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278(5341):1295-1300
3. Palmer S, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105(10):3879-3884
4. Ramratnam B, et al. (2000) The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 6(1):82-85
5. Buzón MJ, et al. (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16(4):460-465
6. Dinoso JB, et al. (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 106(23):9403-9408
7. Joos B, et al.; Swiss HIV Cohort Study (2008) HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA 105(43):16725-16730
8. Saez-Cirión A, et al.; ANRS VISCONTI Study Group (2013) Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 9(3):e1003211
9. Durand CM, Blankson JN, Siliciano RF (2012) Developing strategies for HIV-1 eradication. Trends Immunol 33(11):554-562
10. Archin NM, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487(7408):482-485
11. Hakre S, Chavez L, Shirakawa K, Verdin E (2011) Epigenetic regulation of HIV latency. Curr Opin HIV AIDS 6(1):19-24
12. Chan JK, Greene WC (2011) NF-?B/Rel: Agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS 6(1):12-18
13. Van Lint C, Bouchat S, Marcello A (2013) HIV-1 transcription and latency: An update. Retrovirology 10:67
14. Vozzolo L, et al. (2010) Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein. J Biol Chem 285(50):39314-39328
15. Roesch F, et al. (2012) Hyperthermia stimulates HIV-1 replication. PLoS Pathog 8(7): e1002792
16. Brandt GE, Blagg BS (2009) Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Curr Top Med Chem 9(15):1447-1461
17. Jordan A, Bisgrove D, Verdin E (2003) HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 22(8):1868-1877
18. Williams SA, et al. (2004) Prostratin antagonizes HIV latency by activating NF-kappaB. J Biol Chem 279(40):42008-42017
19. Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: Are we there yet? Clin Cancer Res 18(1):64-76
20. Prodromou C, et al. (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90(1):65-75
21. Stebbins CE, et al. (1997) Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 89(2):239-250
22. Kitson RR, et al. (2013) Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90. Nat Chem 5(4):307-314
23. Kitson RR, Moody CJ (2013) An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors-potential therapeutics in cancer and neurodegeneration. Chem Commun (Camb) 49(76):8441-8443
24. Brough PA, et al. (2008) 4,5-diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. J Med Chem 51(2):196-218
25. Van Lint C, Emiliani S, Ott M, Verdin E (1996) Transcriptional activation and chromatin remodelingof theHIV-1 promoter in response tohistone acetylation.EMBOJ 15(5):1112-1120
26. Favata MF, et al. (1998) Identification of a novel inhibitor of mitogen-Activated protein kinase kinase. J Biol Chem 273(29):18623-18632
27. Dorn GW, 2nd, Mochly-Rosen D (2002) Intracellular transport mechanisms of signal transducers. Annu Rev Physiol 64:407-429
28. Qatsha KA, Rudolph C, Marmé D, Schächtele C, May WS (1993) Gö 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level-producing reservoir cells in vitro. Proc Natl Acad Sci USA 90(10):4674-4678
29. Toullec D, et al. (1991) The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 266(24):15771-15781
30. Trushin SA, et al. (2005) Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta. J Virol 79(15):9821-9830
31. Vallabhapurapu S, Karin M (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27:693-733
32. Traenckner EB, et al. (1995) Phosphorylation of human I kappa B-Alpha on serines 32 and 36 controls I kappa B-Alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 14(12):2876-2883
33. Mercurio F, et al. (1997) IKK-1 and IKK-2: Cytokine-Activated IkappaB kinases essential for NF-kappaB activation. Science 278(5339):860-866
34. Maiuri P, et al. (2011) Fast transcription rates of RNA polymerase II in human cells. EMBO Rep 12(12):1280-1285
35. Chen G, Cao P, Goeddel DV (2002) TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 9(2):401-410
36. Field N, et al. (2003) KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci 116(Pt 18): 3721-3728
37. Li J, Soroka J, Buchner J (2012) The Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperones. Biochim Biophys Acta 1823(3):624-635
38. Friman S, et al. (2011) Sotrastaurin, a novel small molecule inhibiting protein-kinase C: Randomized phase II study in renal transplant recipients. Am J Transplant 11(7):1444-1455
39. Nabel G, Baltimore D (1987) An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326(6114):711-713
40. Pearl LH, Prodromou C, Workman P (2008) The Hsp90 molecular chaperone: An open and shut case for treatment. Biochem J 410(3):439-453
41. Stanley SK, Bressler PB, Poli G, Fauci AS (1990) Heat shock induction of HIV production from chronically infected promonocytic and T cell lines. J Immunol 145(4):1120-1126
42. Lee CT, Zhong L, Mace TA, Repasky EA (2012) Elevation in body temperature to fever range enhances and prolongs subsequent responsiveness of macrophages to endotoxin challenge. PLoS ONE 7(1):e30077
43. Lee MN, et al. (2013) Identification of regulators of the innate immune response to cytosolic DNA and retroviral infection by an integrative approach. Nat Immunol 14(2): 179-185
44. Sawarkar R, Sievers C, Paro R (2012) Hsp90 globally targets paused RNA polymerase to regulate gene expression in response to environmental stimuli. Cell 149(4):807-818
45. O'Keeffe B, Fong Y, Chen D, Zhou S, Zhou Q (2000) Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. J Biol Chem 275(1):279-287
46. Deeken JF, et al. (2012) The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 55(9):1228-1235
47. Bower M, et al. (2008) Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. Blood 111(8):3986-3990
48. Chen W, Sin SH, Wen KW, Damania B, Dittmer DP (2012) Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog 8(11):e1003048
49. Nayar U, et al. (2013) Targeting the Hsp90-Associated viral oncoproteome in gammaherpesvirus-Associated malignancies. Blood 122(16):2837-2847
50. Prichard MN, Prichard LE, Shipman C, Jr. (1993) Strategic design and threedimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother 37(3):540-545
51. Feng JY, et al. (2009) The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: A mechanism of action study. Retrovirology 6:44
52. Prichard MN, Aseltine KR, Shipman C (1993) MacSynergy II (University of Michigan, Ann Arbor, MI).